Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic SyndromesInterventions: Drug: lenalidomide; Biological: epoetin alfa; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Recruiting - verified June 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic SyndromesInterventions: Drug: lenalidomide; Biological: epoetin alfa; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic SyndromeInterventions: Drug: Lenalidomide; Biological: Epoetin Alfa; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2009 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
Condition: AnemiaInterventions: Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta); Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]Sponsor: Hoffmann-La RocheActive, not recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 15, 2008 Category: Research Source Type: clinical trials
